NEW YORK, NY--(Marketwired - Apr 30, 2014) - Plandaí Biotechnology (OTCQB: PLPL) has been given the go-ahead to conduct human clinical trials in a 3-month study that will compare the oral bioavailability in the company's Phytofare^T Catechin Complex to green tea extracts. In this study, to be conducted at the North West University in Potchefstroom, South Africa, Plandaí's 2 technologies, hydrodynamic sheering and Pheroid^® entrapment, will be put to the test versus a product that hasn't undergone these processes.
Reported by Marketwired 2 hours ago.
↧